{
    "name": "ranibizumab intravitreal injection",
    "comment": "Rx",
    "other_names": [
        "Lucentis",
        "Byooviz",
        "ranibizumab-nuna",
        "ranibizumab-eqrn",
        "Cimerli"
    ],
    "classes": [
        "Macular Degeneration Agents",
        "Ophthalmics",
        "VEGF Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/lucentis-byooviz-ranibizumab-intravitreal-injection-343645",
    "pregnancy": {
        "common": [
            "There are no adequate and well-controlled studies in pregnant women",
            "Administration of ranibizumab to pregnant monkeys throughout the period of organogenesis resulted in a low incidence of skeletal abnormalities at intravitreal doses 13-times the predicted human exposure (based on maximal serum trough levels [Cmax]) after a single eye treatment at the recommended clinical dose",
            "Ranibizumab should be given to a pregnant woman only if clearly needed"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "There are no data available on presence of ranibizumab in human milk; effects of ranibizumab on breastfed infant or effects of ranibizumab on milk production/excretion; developmental and health benefits of breastfeeding should be considered along with motherâ€™s clinical need for therapy and any potential adverse effects on breastfed child from ranibizumab"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Ocular/periocular infections"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hypersensitivity reactions may manifest as severe intraocular inflammation",
                "Risk of endophthalmitis or retinal detachment with intravitreous injections; proper aseptic injection technique should always be used when administering therapy; patients should be monitored following the injection to permit early treatment should an infection occur",
                "Possibility of IOP increase within 60 min of intravitreal injection; monitor intraocular pressure prior to and following intravitreal injection with drug and manage appropriately",
                "Potential for adverse thromboembolic events (eg, nonfatal stroke, nonfatal MI, vascular death)",
                "Temporary visual disturbances may occur",
                "Fatal events occurred more frequently in patients with diabetic macular edema and diabetic retinopathy at baseline, who were treated monthly compared with control",
                "No studies on effects of ranibizumab on fertility conducted; not known whether ranibizumab can affect reproduction capacity; based on anti-VEGF mechanism of action for ranibizumab, therapy may pose risk to reproductive capacity"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "verteporfin",
            "description": {
                "common": "ranibizumab intravitreal injection increases toxicity of verteporfin by unspecified interaction mechanism. Use Caution/Monitor. Risk of severe intraocular inflammation, even when separated by 7 days."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Conjunctival hemorrhage",
            "percent": "43-77"
        },
        {
            "name": "Eye pain",
            "percent": "17-37"
        },
        {
            "name": "Vitreous floaters",
            "percent": "3-32"
        },
        {
            "name": "Increased intraocular pressure",
            "percent": "8-24"
        },
        {
            "name": "IOP",
            "percent": "7-22"
        },
        {
            "name": "Vitreous detachment",
            "percent": "4-19"
        },
        {
            "name": "Eye irritation",
            "percent": "5-18"
        },
        {
            "name": "Intraocular inflammation",
            "percent": "2-15"
        },
        {
            "name": "Headache",
            "percent": "2-15"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "13"
        },
        {
            "name": "Retinal disorder",
            "percent": "3-13"
        },
        {
            "name": "Blepharitis",
            "percent": "1-11"
        },
        {
            "name": "Retinal degeneration",
            "percent": "9"
        },
        {
            "name": "Conjunctival hyperemia",
            "percent": "8"
        },
        {
            "name": "Posterior capsule opacification",
            "percent": "5"
        },
        {
            "name": "Injection site hemorrhage",
            "percent": "4"
        },
        {
            "name": "Vitreous hemorrhage",
            "percent": null
        },
        {
            "name": "Ocular",
            "percent": null
        },
        {
            "name": "Tear of retinal pigment epithelium among patients with neovascular AMD",
            "percent": null
        }
    ]
}